Reversing the curse on PPARγ.
Level V
Where this comes from
- Record sourced from PubMed, PMID 29757190.
- Also identified by DOI 10.1172/JCI121392 and PMC identifier 5983334.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thiazolidinediones (TZDs) are the only antidiabetic drugs that reverse insulin resistance. They have been a valuable asset in the treatment of type 2 diabetes, but their side effects have curtailed widespread use in the clinic. In this issue of the JCI, Kraakman and colleagues provide evidence that deacetylation of the nuclear receptor PPARγ improves the therapeutic index of TZDs. These findings should revitalize the quest to employ insulin sensitization as a first-line approach to managing type 2 diabetes.
Medical subject headings
- Diabetes Mellitus, Type 2
- Thiazolidinediones